Article
Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.
Hepato-gastroenterology - 1 Jan 2000
Zhang Ya-li, Zhang Jie, Cui Li-yan
Abstract excerpt
BACKGROUND/AIMS: Tyrosine-methionine-aspartate-aspartate (YMDD) mutations were the main limitation of lamivudine (LAM) for treating chronic hepatitis B (CHB). The aim of this study was to evaluate whether LAM combined with IFN-α offer advantage over lamivudine monotherapy for the occurrence of YMDD mutations in CHB using a meta-analysis. METHODOLOGY: We searched electronic databases and calculated the odds ratios...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.